What does this research mean for the field?

Baseline levels of CRP, complement C4, and IL-6, but not their in-treatment kinetics, are prognostically relevant for clinical outcomes in PD-L1 high non-small cell lung cancer patients treated with pembrolizumab. Novelty: ClaimNovelty.INCREMENTAL. Consensus alignment: ConsensusAlignment.NEUTRAL.

What question did this study set out to answer?

The study aims to evaluate the prognostic relevance of peripheral blood immune markers during pembrolizumab treatment in PD-L1 high non-small cell lung cancer patients.

May 20, 2026CancersOpen Access

In-Treatment Kinetics of Peripheral Blood Immune Markers in PD-L1 High Non-Small Cell Lung Cancer and Prognostic Relevance for Immunotherapy Outcomes

View Full Paper

Ask AI

Bookmark

Authors

ITIoannis P. TrontzasSotiria General Hospital IGIoanna-Evdokia GalaniAcademy of Athens EPEmmanouil PanagiotouSotiria General Hospital

Discussion

Member takes

Implication

Prospective trial measures immune markers in PD-L1 high NSCLC to explore treatment outcome predictions, implying potential for future research.

Key Points

The study aims to evaluate the prognostic relevance of peripheral blood immune markers during pembrolizumab treatment in PD-L1 high non-small cell lung cancer patients.
Prospective measurement of PBIMs in 31 PD-L1 high NSCLC patients receiving pembrolizumab monotherapy.
Kinetics analyzed at baseline and multiple time points during the first year of treatment.
Associations with clinical outcomes explored after a 2-year follow-up.
Significant decrease in CRP, IL-17α, IL-6, and IL-8 levels over the first year of treatment.
Higher baseline CRP, complement C4, and IL-6 were associated with poorer clinical outcomes, with C4 retaining independent prognostic significance.
Integration of these markers into composite indices improved prognostic performance.

Cite This Study

Trontzas et al. (2026) studied this question.

synapsesocial.com/papers/6a0d4fa9f03e14405aa9b11f https://doi.org/10.3390/cancers18101623

View Full Paper

Ask AI

Bookmark

Implication

Prospective trial measures immune markers in PD-L1 high NSCLC to explore treatment outcome predictions, implying potential for future research.

In-Treatment Kinetics of Peripheral Blood Immune Markers in PD-L1 High Non-Small Cell Lung Cancer and Prognostic Relevance for Immunotherapy Outcomes

Discussion

Member takes

Implication

Key Points

Cite This Study

In-Treatment Kinetics of Peripheral Blood Immune Markers in PD-L1 High Non-Small Cell Lung Cancer and Prognostic Relevance for Immunotherapy Outcomes

Discussion

Member takes

Implication

Key Points

Cite This Study

Also Consider

Also Consider